Swan Capital’s GSK GSK Stock Holding History

Swan Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.91K	Sell	89 -200	-69%	-$10.8K	﹤0.01%	262
2025 Q4	$14.2K	Hold	289	–	–	0.01%	150
2025 Q3	$12.5K	Sell	289 -110	-28%	-$4.3K	0.01%	147
2025 Q2	$15.3K	Buy	399 +119	+43%	+$4.55K	0.01%	132
2025 Q1	$10.8K	Hold	280	–	–	0.01%	137
2024 Q4	$9.47K	Hold	280	–	–	﹤0.01%	136
2024 Q3	$11.4K	Hold	280	–	–	0.01%	136
2024 Q2	$10.8K	Buy	+280	New	+$11.8K	0.01%	126

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Swan Capital's GSK Position: Q1 2026 in Review

Swan Capital reduced its GSK (GSK) stake by 69% in Q1 2026, selling an estimated $10.8K and leaving 89 shares worth $4.91K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

Swan Capital first reported a position in GSK in Q2 2024 and has held it in 8 quarters since. The position peaked at $15.3K in Q2 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Swan Capital held 89 shares of GSK worth $4.91K as of Q1 2026.
Swan Capital sold 200 GSK shares in Q1 2026, an estimated $10.8K.
GSK made up ﹤0.01% of Swan Capital's portfolio in Q1 2026, its #262 holding.
Swan Capital first reported a position in GSK in Q2 2024 and has held it in 8 quarters since.
Swan Capital's GSK position peaked at $15.3K in Q2 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.